These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30471053)

  • 21. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
    Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
    Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving.
    Lodemann E; Bockisch A; Görges R
    Psychoneuroendocrinology; 2012 Oct; 37(10):1726-35. PubMed ID: 22541716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review.
    Sunavala-Dossabhoy G; Petti S
    Oral Oncol; 2023 Jan; 136():106280. PubMed ID: 36525783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
    Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
    Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
    J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients.
    An YS; Lee J; Kim HK; Lee SJ; Yoon JK
    Sci Rep; 2023 Jan; 13(1):206. PubMed ID: 36604466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant Human Thyrotropin Worsens Renal Cortical Perfusion and Renal Function in Patients After Total Thyroidectomy Due to Differentiated Thyroid Cancer.
    Saracyn M; Lubas A; Bober B; Kowalski Ł; Kapusta W; Niemczyk S; Wartofsky L; Kamiński G
    Thyroid; 2020 May; 30(5):653-660. PubMed ID: 31964314
    [No Abstract]   [Full Text] [Related]  

  • 30. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
    Rosario PW; Calsolari MR
    Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population.
    Tang CYL; Thang SP; Zaheer S; Kwan CK; Ng DC
    Endocrine; 2020 Jul; 69(1):126-132. PubMed ID: 32112240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
    Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
    Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.
    Kwon TE; Pasqual E; Kitahara CM; Lee C
    J Radiol Prot; 2023 May; 43(2):. PubMed ID: 37196645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight Changes in Patients with Differentiated Thyroid Carcinoma during Postoperative Long-Term Follow-up under Thyroid Stimulating Hormone Suppression.
    Sohn SY; Joung JY; Cho YY; Park SM; Jin SM; Chung JH; Kim SW
    Endocrinol Metab (Seoul); 2015 Sep; 30(3):343-51. PubMed ID: 26248858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.
    Kowalska A; Pałyga I; Gąsior-Perczak D; Walczyk A; Trybek T; Słuszniak A; Mężyk R; Góźdź S
    PLoS One; 2015; 10(7):e0133852. PubMed ID: 26230494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
    Liepe K
    Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration.
    Lee H; Paeng JC; Choi H; Cho SW; Park YJ; Park DJ; Lee YA; Chung JK; Kang KW; Cheon GJ
    PLoS One; 2021; 16(9):e0256727. PubMed ID: 34492048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.